Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents

• Main Authors: Chengliang Sun (Author), Yao Cheng (Author), Xiaojia Liu (Author), Gefei Wang (Author), Wenjian Min (Author), Xiao Wang (Author), Kai Yuan (Author), Yi Hou (Author), Jiaxing Li (Author), Haolin Zhang (Author), Haojie Dong (Author), Liping Wang (Author), Chenguang Lou (Author), Yanze Sun (Author), Xinmiao Yu (Author), Hongbin Deng (Author), Yibei Xiao (Author), Peng Yang (Author)
• Format: Book
• Published: Elsevier, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) have emerged as one of the most promising immune checkpoint targets for cancer immunotherapy. Despite the inherent advantages of small-molecule inhibitors over antibodies, the discovery of small-molecule inhibitors has fallen behind...